203 related articles for article (PubMed ID: 23724525)
1. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
Dolapcioglu K; Boz A; Baloglu A
Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
3. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
Karimi-Zarchi M; Dehghani-Firoozabadi R; Tabatabaie A; Dehghani-Firoozabadi Z; Teimoori S; Chiti Z; Miratashi-Yazdi A; Dehghani A
Clin Exp Obstet Gynecol; 2013; 40(3):421-4. PubMed ID: 24283179
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
Ismail MT; Fahmy DM; Elshmaa NS
Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322
[TBL] [Abstract][Full Text] [Related]
6. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
[TBL] [Abstract][Full Text] [Related]
7. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
8. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
9. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Ørbo A; Arnes M; Vereide AB; Straume B
BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
[TBL] [Abstract][Full Text] [Related]
10. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
12. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
13. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
14. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
[TBL] [Abstract][Full Text] [Related]
15. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
Abu Hashim H; Ghayaty E; El Rakhawy M
Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
[TBL] [Abstract][Full Text] [Related]
16. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
[TBL] [Abstract][Full Text] [Related]
18. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
Kim NK; Choi CH; Seong SJ; Lee JM; Lee B; Kim K
Gynecol Oncol; 2024 Apr; 183():68-73. PubMed ID: 38520881
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
